We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Cepheid to Sponsor BASHH 2013 Spring Meeting

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Event is where the latest healthcare trends and scientific breakthroughs in this important field will be discussed.
A platinum sponsor of the event – held from the 15th to the 17th of May in Bristol – Cepheid will be showcasing the latest addition to the GeneXpert® test menu, Xpert® CT/NG, on booth 19 at the accompanying exhibition.

The meeting’s diverse programme includes a Cepheid-sponsored lecture on Assessing the costs and benefits of point of care tests for STIs from invited speaker Dr Elisabeth Adams, Director and Founder of Aquarius Population Health and an Honorary Researcher at the University of Bristol. Visitors to the Cepheid exhibition stand will discover the advantages of the Xpert CT/NG qualitative in vitro molecular diagnostic test for the rapid detection and differentiation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). This easy-to-use, FDA-approved and CE-marked on-demand molecular test uses two independent NG DNA targets for high specificity and a CT target exclusively selected for superior inclusivity. A Sample Adequacy Control (SAC) is also included, to prevent false negative results where no human cells are present. Accurate results are delivered in just 90 minutes, contributing to effective patient and disease management by giving clinicians the opportunity to provide same-day consultation and treatment.